PLYX
Polaryx Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$368.80M
P/E Ratio
—
EPS
$-0.19
Beta
—
52W High
$48.91
52W Low
$2.20
50-Day MA
$6.40
200-Day MA
$6.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. The company is headquartered in Paramus, New Jersey.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -193.70% |
| Return on Assets | -96.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.10 |
| Price-to-Book | 63.37 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $47.34M |
| Float | $4.98M |
| % Insiders | 52.80% |
| % Institutions | 0.00% |
Analyst Ratings
Consensus ($10.00 target)
1
Strong BuyData last updated: 4/14/2026